$MED

Insider Stock Purchases: August 28, 2026

On August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.

Original reporting
Published Aug 28, 2026, 6:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Stock Purchases: August 28, 2026 — source image
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

These filings provide fresh, primary‑source data but involve modest transaction sizes, limiting immediate trading relevance.

02

Market read

Insider buying signals modest confidence but transaction sizes are small; overall market impact is low.

03

What to watch

Potential upcoming corporate actions or clinical trial news not disclosed yet.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates recent Form 4 insider purchase filings reported by QuiverQuant for August 28 2026.

Company-level read

Ticker impact

$MEDNeutralMedium confidence
Context

Medifast Inc. insider Kiai Parsa purchased 41,975 shares for $514,747 on 08/26.

Expected impact

Potential slight price uptick if market perceives confidence.

Evidence & confidence

Purchase size is modest relative to market cap; limited immediate impact.

$RGNXNeutralMedium confidence
Context

Regenxbio Inc. insider Gregory Austin bought 53,407 shares for $499,675 on 08/27.

Expected impact

Minimal short‑term effect; may support slight bullish bias.

Evidence & confidence

Buy amount is under $1M, typical for biotech insiders, unlikely to move price materially.

$HWKNNeutralLow confidence
Context

Hawkins Inc. insider Douglas Lange bought 910 shares for $108,065 on 08/25.

Expected impact

Negligible impact.

Evidence & confidence

Purchase is tiny relative to float; market likely ignores.

$FTCINeutralLow confidence
Context

FTC Solar, Inc. insider Shaker Sadasivam purchased 33,290 shares for $72,905 on 08/26.

Expected impact

Little to no price movement expected.

Evidence & confidence

Purchase amount is modest; market reaction expected to be muted.

Market effects

Limited; insider activity in health and renewable sectors may be noted by sector traders.

None significant.

Low.

Counterpoint

Insider purchases are routine and may not indicate real upside; focus on fundamentals.

Key entities

  • Medifast Inc.

    Health and nutrition company; insider purchases reported.

  • Regenxbio Inc.

    Biotech firm; insider purchase reported.

  • Hawkins Inc.

    Water treatment company; insider purchase reported.

  • FTC Solar, Inc.

    Solar energy firm; insider purchase reported.

Related articles

$RGNXMedAI 8/10

Why is Regenxbio stock climbing today?

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

$AKAMMed

Nasdaq, S&P 500 Futures Rise Despite Surging Treasury Yields: AMD, TSLA, SPCX, AKAM, BE Stocks In Focus

Nasdaq and S&P 500 futures rose despite surging Treasury yields. Akamai (AKAM) surged 20% after a $11.6B deal with Anthropic. Tesla (TSLA) trended upward following a next-gen Roadster unveil and Semi truck production news. SpaceX (SPCX) gained on AI model predictions. Bloom Energy (BE) rose 1% after reaffirming Oracle's (ORCL) fuel-cell contract. Comcast (CMCSA) fell on analyst downgrades. Regenxbio (RGNX) rose 2% on positive gene therapy data.

$RGNXMedAI 8/10

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO (Nasdaq: RGNX) presented positive three-year data from its Phase II ALTITUDE study of surabgene lomparvovec for diabetic retinopathy at the Retina Society Annual Meeting. The data showed durable efficacy with 60% of participants achieving a >2-step improvement on the DRSS. No new safety signals were observed. The company is advancing the treatment in a Phase IIb/III trial.